Hadzikadic-Gusic L - Search Results

1

Changes in margin re-excision rates: Experience incorporating the "no ink on tumor" guideline into practice.

Patten CR, Walsh K, Sarantou T, Hadzikadic-Gusic L, Forster MR, Robinson M, White RL Jr. Patten CR, et al. J Surg Oncol. 2017 Dec;116(8):1040-1045. doi: 10.1002/jso.24770. Epub 2017 Jul 27. J Surg Oncol. 2017. PMID: 28750136

2

Margin width is not predictive of residual disease on re-excision in breast conserving therapy.

Hadzikadic Gusic L, McGuire KP, Ozmen T, Soran A, Thomas CR, McAuliffe PF, Diego EJ, Bonaventura M, Johnson RR, Ahrendt GM. Hadzikadic Gusic L, et al. J Surg Oncol. 2014 Apr;109(5):426-30. doi: 10.1002/jso.23530. Epub 2013 Dec 11. J Surg Oncol. 2014. PMID: 24338603

3

Margin re-excision and local recurrence in invasive breast cancer: A cost analysis using a decision tree model.

Abe SE, Hill JS, Han Y, Walsh K, Symanowski JT, Hadzikadic-Gusic L, Flippo-Morton T, Sarantou T, Forster M, White RL Jr. Abe SE, et al. J Surg Oncol. 2015 Sep;112(4):443-8. doi: 10.1002/jso.23990. Epub 2015 Sep 16. J Surg Oncol. 2015. PMID: 26374088

4

Rate of radial scars by core biopsy and upgrading to malignancy or high-risk lesions before and after introduction of digital breast tomosynthesis.

Phantana-Angkool A, Forster MR, Warren YE, Livasy CA, Sobel AH, Beasley LM, Trufan SJ, Hadzikadic-Gusic L, Sarantou T, Voci AE, Sarma D, White RL Jr. Phantana-Angkool A, et al. Breast Cancer Res Treat. 2019 Jan;173(1):23-29. doi: 10.1007/s10549-018-4973-x. Epub 2018 Sep 21. Breast Cancer Res Treat. 2019. PMID: 30242581

5

Ductal Carcinoma In Situ with Microinvasion on Core Biopsy: Evaluating Tumor Upstaging Rate, Lymph Node Metastasis Rate, and Associated Predictive Variables.

Phantana-Angkool A, Voci AE, Warren YE, Livasy CA, Beasley LM, Robinson MM, Hadzikadic-Gusic L, Sarantou T, Forster MR, Sarma D, White RL Jr. Phantana-Angkool A, et al. Ann Surg Oncol. 2019 Nov;26(12):3874-3882. doi: 10.1245/s10434-019-07604-4. Epub 2019 Jul 24. Ann Surg Oncol. 2019. PMID: 31342378

6

Single surgeon versus co-surgeon bilateral mastectomy: Comparing outcomes and costs based on health economic modeling from the perspective of the hospital system.

Hudson L, Reese E, Hecksher A, Schepel C, Trufan SJ, Cruz A, Verbyla A, White RL, Hadzikadic-Gusic L. Hudson L, et al. J Surg Oncol. 2022 Aug;126(2):239-246. doi: 10.1002/jso.26891. Epub 2022 Apr 12. J Surg Oncol. 2022. PMID: 35411951

7

Does Residual Cancer Burden Predict Local Recurrence After Neoadjuvant Chemotherapy?

Pestana CV, Livasy CA, Donahue EE, Neelands B, Tan AR, Sarantou T, Hadzikadic-Gusic L, White RL Jr. Pestana CV, et al. Ann Surg Oncol. 2022 Nov;29(12):7716-7724. doi: 10.1245/s10434-022-12038-6. Epub 2022 Jul 9. Ann Surg Oncol. 2022. PMID: 35810226

8

Residual Cancer Burden Class Associated with Survival Outcomes in Women with Different Phenotypic Subtypes of Breast Cancer After Neoadjuvant Chemotherapy.

Elder EA, Livasy CA, Donahue EE, Neelands B, Patrick A, Needham M, Sarantou T, Hadzikadic-Gusic L, Heeke AL, White RL Jr. Elder EA, et al. Among authors: hadzikadic gusic l. Ann Surg Oncol. 2022 Dec;29(13):8060-8069. doi: 10.1245/s10434-022-12300-x. Epub 2022 Aug 18. Ann Surg Oncol. 2022. PMID: 35980548

9

[No title available]

[No authors listed] [No authors listed] PMID: 36057896

10

[No title available]

[No authors listed] [No authors listed] PMID: 36100831

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

22 results

Search Page

Filters